Evidence map›Paper›PMID 40394833›Full record

ArticleAngiology2026

FGF-23 and Long-term Outcome in Peripheral Artery Disease.

Bernhard Zierfuss, Marija Bojic, Gerit-Holger Schernthaner, Clemens Höbaus

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bernhard ZierfussDivision of Angiology, Medicine II, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-3225-9063
Marija Bojic1st Medical Department, Hanusch Hospital, Vienna, Austria.
Gerit-Holger SchernthanerDivision of Angiology, Medicine II, Medical University of Vienna, Vienna, Austria.
Clemens HöbausDivision of Angiology, Medicine II, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9704-1452

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerotic peripheral artery disease (PAD) and chronic kidney disease (CKD) are highly interconnected diseases, while causes for excess mortality are not well-defined. Fibroblast growth-factor 23 (FGF-23) is elevated in mineral bone disease of CKD and was shown to be associated with higher mortality. However, it is not known if this association extends to PAD. FGF-23 was measured by ELISA in serum samples of 298 patients with stable PAD (Fontaine stage I-II) with an estimated glomerular filtration rate (eGFR) of 72 (58-85) ml/min. Mortality was assessed after a long-term follow-up of up to 10 years. FGF-23 showed significant associations with markers of metabolic syndrome (triglycerides

Indexed as

Fibroblast Growth FactorsPeripheral Arterial DiseaseAgedBiomarkersFemaleFibroblast Growth Factor-23Glomerular Filtration RateHumansMaleMiddle AgedRenal Insufficiency, ChronicRisk FactorsTime FactorsBiomarkersFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth Factorschronic kidney diseaseFGF-23mortalityperipheral artery disease

Identifiers

PMID40394833
PMCPMC13047214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.